Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis
Jeroen R. Dijkstra, Frank J.M. Opdam, Jerry Boonyaratanakornkit et al. · Journal of Molecular Diagnostics · 2012
Cited by 15 works. doi:10.1016/j.jmoldx.2012.01.002 Open-access PDF
Authors
- Jeroen R. Dijkstra
- Frank J.M. Opdam
- Jerry Boonyaratanakornkit
- E. Ralf Schönbrunner
- Mona D. Shahbazian
- Anders Edsjö
- Gerald Höefler
- Andreas Jung
- Athanassios Kotsinas
- Vassilis G. Gorgoulis
- Fernando López‐Ríos
- Karin de Stricker
- Étienne Rouleau
- Bart Biesmans
- J. Han van Krieken
References
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- Reference materials and commutability.
- A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations
- External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds
- High sensitivity of both sequencing and real‐time PCR analysis of KRAS mutations in colorectal cancer tissue